Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries.

Jansen I, Uddman R, Ekman R, Olesen J, Ottosson A, Edvinsson L

Peptides1 May 1992Cited by 87 (Europe PMC)

PMID1381830DOI10.1016/0196-9781(92)90084-gPepBankPUB-01381830

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueEfficacy outcome
In isolated human middle meningeal, cerebral and temporal arteries, VIP relaxed all three types of cephalic arteries.
In plain wordsIn lab tests on human head arteries, VIP relaxed all three artery types tested.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseRelaxation of cephalic arteries by VIP
Study
humann: not reported in source
Isolated human middle meningeal, cerebral and temporal arteries
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Vasoactive intestinal polypeptide, peptide histidine methionine-27, SP, neurokinin A, and CGRP relaxed all three types of cephalic arteries.
1 context sentence(design, population, supporting numbers)
Summary · context
In isolated ring segments of human middle meningeal and cerebral arteries
Report a problemFND-0138183004
02LabEx vivo tissueEfficacy outcome
In human cephalic arteries from different regions, the responses to VIP and substance P showed a similar pattern of reactivity.
In plain wordsIn lab tests on human head arteries, VIP and substance P gave similar response patterns across artery regions.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableRegional pattern of response to VIP versus substance P
Study
humann: not reported in source
Isolated human middle meningeal, cerebral and temporal arteries
Comparator
Substance P
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Comparison of the responses to VIP and SP of vessels from the different regions showed a similar pattern of reactivity.
1 context sentence(design, population, supporting numbers)
Summary · context
In isolated ring segments of human middle meningeal and cerebral arteries
Report a problemFND-0138183006

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

03LabEndogenous levelEx vivo tissueOther
In human middle meningeal arteries, a sparse to moderate supply of nerve fibers containing the body's own VIP-like immunoreactivity was found in the vessel walls.
In plain wordsIn human artery tissue, nerve fibers containing the body's own VIP were found in the vessel walls, in sparse to moderate amounts.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP-like nerve fibers in middle meningeal arteries
Study
humann: not reported in source
Isolated human middle meningeal, cerebral and temporal arteries
Outcome group
Endogenous peptide levels · Nervous system and cognition
Source sentences
Summary
A sparse to moderate supply of nerve fibers containing neuropeptide Y-like immunoreactivity (NPY-LI), vasoactive intestinal polypeptide (VIP-LI), substance P (SP-LI), and calcitonin gene-related peptide (CGRP-LI) was demonstrated in the walls of human middle meningeal arteries.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0138183001
04LabEndogenous levelEx vivo tissueOther
In human middle meningeal arteries, the distribution and density of nerve fibers with the body's own VIP-like immunoreactivity were similar to those in cerebral and temporal arteries.
In plain wordsIn human artery tissue, the body's own VIP nerve fibers were similarly spread and dense in meningeal, cerebral and temporal arteries.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeVIP-like nerve fiber distribution compared with cerebral and temporal arteries
Study
humann: not reported in source
Isolated human middle meningeal, cerebral and temporal arteries
Comparator
Human cerebral and temporal arteries
Outcome group
Endogenous peptide levels · Nervous system and cognition
Source sentences
Summary
Comparison with similar studies on human cerebral and temporal arteries indicated a similar distribution and density.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0138183002
05LabEndogenous levelEx vivo tissueOther
In extracts of human cephalic arteries, the major peak of VIP-like immunoreactivity eluted at about the same volume as synthetic VIP.
In plain wordsIn human artery extracts, the body's own VIP-like material behaved like synthetic VIP in chemical separation.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableHPLC characterization of VIP-like immunoreactivity
Study
humann: not reported in source
Isolated human middle meningeal, cerebral and temporal arteries
Outcome group
Endogenous peptide levels · Nervous system and cognition
Source sentences
Summary
The immunoreactive material in all three arterial regions was characterized by reversed-phase high pressure liquid chromatography (HPLC) and radioimmunoassay (RIA). The major peak of NPY-LI, VIP-LI, SP-LI, and CGRP-LI in each extract eluted approximately with the same elution volume as that of the c…
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0138183003

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
In isolated human cephalic arteries, the relaxing effects of VIP and the other tested peptides were not antagonized by propranolol, atropine or cimetidine.
In plain wordsIn lab tests on human head arteries, three blocking drugs did not stop the relaxing effect of VIP and the other peptides.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeEffect of propranolol, atropine and cimetidine on peptide-induced relaxation
Study
humann: not reported in source
Isolated human middle meningeal, cerebral and temporal arteries
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
The peptide effects were not antagonized by propranolol, atropine, or cimetidine.
1 context sentence(design, population, supporting numbers)
Summary · context
In isolated ring segments of human middle meningeal and cerebral arteries
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0138183005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.